02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
08:00 , Mar 10, 2016 |  BC Innovations  |  Targets & Mechanisms

Brown fat heats up

While FGF21 is the clear frontrunner target for stimulating brown and beige fat, players in the seven year-old field believe there's room for plenty more runners in the race. Since the start of the year,...